Union City, CA, United States of America

Meng Sui


Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Union City, CA (US) (2006 - 2008)
  • Sunnyvale, CA (US) (2010)

Company Filing History:


Years Active: 2006-2010

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Meng Sui

Introduction

Meng Sui is a prominent inventor based in Union City, CA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 4 patents. His work focuses on developing novel compounds that have potential therapeutic applications.

Latest Patents

Meng Sui's latest patents include innovative compounds such as indole and benzofuran 2-carboxamide derivatives. These compounds are described as having specific formulas and pharmaceutically acceptable salts, with methods for preparing and using them outlined in the patent. Another notable patent involves quinazolinone and benzoxazinone derivatives, which are also detailed with specific formulas. These compounds are aimed at treating central nervous system diseases, showcasing Meng Sui's commitment to addressing critical health issues.

Career Highlights

Meng Sui is currently associated with Roche Palo Alto LLC, where he continues to advance his research and development efforts. His work has contributed to the understanding and potential treatment of various medical conditions through innovative chemical compounds.

Collaborations

Meng Sui has collaborated with notable colleagues in his field, including Shu-Hai Zhao and Nancy Elisabeth Krauss. These partnerships have likely enhanced the scope and impact of his research.

Conclusion

Meng Sui's contributions to pharmaceutical innovation are noteworthy, with a focus on developing compounds that may lead to significant advancements in medical treatments. His work exemplifies the importance of research and collaboration in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…